

## Application of REGENERESSEN® in the Gynaecologic Practice

G. Linneweber

Hamburg

The most frequent form of malignant tumors with women is the mammal carcinoma. Its very high mortality rate (twelve to fifteen thousand per year in the BRD) is caused by early haematogenous metastases, that can be substantially reduced neither by radical resections nor by a post-operative radiotherapy. In spite of extensive efforts the metastasizing mammal carcinoma must still be regarded as incurable. The usual therapeutic measures have only a palliative function and are accompanied by heavy side effects. For instance, a systemic cytostatic chemotherapy cannot be sustained, if the count of leukocytes is depressed too low.

In such cases the referent tries to preserve as much of the patients' reduced life-quality as possible by means of additional biological treatment, with the aim of an accelerated normalization of the blood count in the intervals of the cytostatic therapy, thus lengthening the periods in which the patient can lead a nearly normal life, and render it possible to proceed with the chemotherapy on schedule.

In this respect the referent has used the REGENERESSEN of *bone marrow* (12 ampoules) and *RN 13* (10 ampoules)

with very good results. In a documented case the count of leukocytes could be raised from 2000 for 13000 and that of thrombocytes from 83000 to 284000 within two weeks, and later on the blood count could be stabilized on a normal level.